Related Experiment Video
Updated: Jul 16, 2026
A Modified Inflammatory Pain Model to Study the Analgesic Effect in Mice
Published on: November 15, 2024
The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats
Angela B Reksidler1, Marcelo M S Lima, Sílvio M Zanata
1Departamento de Farmacologia, Universidade Federal do Paraná, Curitiba, PR, Brazil.
Abstract:
The present study investigated the effects of the selective cyclooxygenase-2 (COX-2) inhibitor parecoxib (Bextratrade mark) in the prevention of motor and cognitive impairments observed in rats after an intranigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a model of the early phase of Parkinson's disease. The treatment with parecoxib (10 mg/kg) administered prior to the surgery and daily (2 mg/kg) for the subsequent 21 days, prevented the MPTP-treated rats from presenting decreased locomotor and exploratory behavior, increased immobility, and impairment while performing the cued version of the Morris water maze. Furthermore, parecoxib treatment also significantly prevented the reduction of tyrosine hydroxylase protein expression in the substantia nigra (7, 14 and 21 days after surgery), and in the striatum (14 and 21 days after surgery) as immunodetected by western blotting. These results strongly suggest that parecoxib exerts a neuroprotective effect on motor, tyrosine hydroxylase expression, and cognitive functions as it prevents their impairments within the confines of this animal model of the early phase of Parkinson's disease.
Insights
Parecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, protected against motor and cognitive deficits in a rat model of Parkinson's disease. It also preserved tyrosine hydroxylase expression, indicating a neuroprotective effect.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor and cognitive impairments.
- The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model mimics early-stage PD, particularly dopaminergic neuron loss in the substantia nigra.
Purpose of the Study:
- To investigate the neuroprotective effects of parecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, in an MPTP-induced rat model of Parkinson's disease.
- To assess parecoxib's impact on motor function, cognitive performance, and tyrosine hydroxylase expression.
Main Methods:
- Rats received MPTP to induce Parkinsonian symptoms.
- Parecoxib was administered before surgery and daily for 21 days.
- Locomotor activity, exploratory behavior, and cognitive function (Morris water maze) were evaluated.
- Tyrosine hydroxylase protein levels in the substantia nigra and striatum were measured using western blotting.
Main Results:
- Parecoxib treatment significantly prevented MPTP-induced decreases in locomotor and exploratory behavior.
- Cognitive impairments in the cued Morris water maze were ameliorated by parecoxib.
- Parecoxib administration preserved tyrosine hydroxylase protein expression in the substantia nigra and striatum.
Conclusions:
- Parecoxib demonstrates significant neuroprotective effects in an early-phase Parkinson's disease rat model.
- The drug preserves motor function, cognitive abilities, and dopaminergic neuron markers.
- These findings suggest potential therapeutic benefits of parecoxib for Parkinson's disease.
